Anemia: A Lesser-Known Side Effect of GLP-1 Drugs?
With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light. Medscape Medical News
GLP-1 Inquiries: Key Points for PCPs and College Students
College students may seek you out over winter break wanting to start a GLP-1. Medscape Medical News
Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist – Slideshow
Metabolic benefits of 1,3-diacylglycerol in type 2 diabetes mellitus and its association with gut microbiota-derived SCFAs-GPR41-GLP-1 signaling
Food Funct., 2026, Accepted ManuscriptDOI: 10.1039/D5FO03164H, Paper Jiaomei Li, Hao Wang, Jiekai Yang, Yicheng Wang, Guo Jia, Jiaojiao Gu1,3-Diacylglycerol (1,3-DAG) is a dietary lipid with known lipid-lowering effects, yet its role in type 2 diabetes mellitus (T2DM) and gut microbiota regulation remains unclear. This study investigated the effects…The content of this RSS Feed (c) The […]
GLP-1 drugs have ‘little or no effect’ on risk of obesity-related cancers, study suggests
Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related cancers, new research suggests.
How the rise of GLP-1 drugs is shifting consumer habits
The rise in the use of GLP-1 weight-loss drugs across the U.S. is shifting not only scales, but also how Americans are spending their time and money. Washington Post retail reporter Jaclyn Peiser explains. CBS News 24/7 is the premier anchored streaming news service from CBS News and Stations that is available free to everyone […]
Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript
GLP-1 receptor agonists likely have little or no effect on obesity-related cancer risk, research shows
A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or overweight or obesity.
The miracle that fades: New study reveals troubling reality of post-treatment weight regain
(NaturalNews) A large-scale study of over 1.2 million patients found that more than half (58%) of those who stop GLP-1 weight-loss drugs like Wegovy and Ozempic…
Weight-loss drug customers were caught up in telehealth scam. Here’s how to avoid being a victim
Federal Trade Commission crackdown on company selling GLP-1 is a reminder of the dangers consumers face when purchasing trending treatments online